Search company, investor...

BioSyntech Canada

biosyntech.com

Founded Year

1994

Stage

PIPE | IPO

About BioSyntech Canada

BioSyntech specializes in the discovery, development and manufacturing of biotherapeutic thermogels for regenerative medicine and therapeutic delivery. Its platform technology is a family of hydrogels that can be injected or applied to specific sites and which offer beneficial properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds.

Headquarters Location

475 Armand-Frappier Blvd.

Laval, Quebec, H7V 4B3,

Canada

450-686-2437

Missing: BioSyntech Canada's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioSyntech Canada's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioSyntech Canada

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioSyntech Canada is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

BioSyntech Canada Frequently Asked Questions (FAQ)

  • When was BioSyntech Canada founded?

    BioSyntech Canada was founded in 1994.

  • Where is BioSyntech Canada's headquarters?

    BioSyntech Canada's headquarters is located at 475 Armand-Frappier Blvd., Laval.

  • What is BioSyntech Canada's latest funding round?

    BioSyntech Canada's latest funding round is PIPE.

  • Who are the investors of BioSyntech Canada?

    Investors of BioSyntech Canada include Pappas Ventures, ProQuest Investments and BDC Healthcare Venture Fund.

  • Who are BioSyntech Canada's competitors?

    Competitors of BioSyntech Canada include Mirus Bio, Erydel, Carbylan Therapeutics, Medgenics, NephRx Corporation and 11 more.

Compare BioSyntech Canada to Competitors

G
Global Protein Products

Global Protein Products (GPP) is a zein protein coatings company. Zein protein is the storage protein in corn kernels. It has excellent film-forming and thermoplastic characteristics.

T
Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

E
Erydel

EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

M
MAD Nanolayers

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.

N
NeXagen

utilized "combinatorial chemistry" technology to discover lead therapeutic and diagnostic compounds.�MACUGEN, approved for wet age-related macular degeneration, was discovered using this technology. Upon NeXagen's merger with Vestar, Inc., the company also marketed and developed liposomal drug delivery products.

K
Kucera Pharmaceutical Company

Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.